Feature | May 14, 2012

Catheter Ablation Superior to Drug Therapy as First-Line Treatment for AFib

Preliminary RAAFT study findings presented at HRS 2012 scientific meeting

May 14, 2012 — Patients with the heart rhythm disorder atrial fibrillation (AFib) who received first-line catheter ablation treatment had a longer arrhythmia-free interval than patients receiving anti-arrhythmic drugs, the standard first-line treatment. The preliminary findings were presented during a late-breaking session at the Heart Rhythm Society (HRS) 2012 scientific sessions last week in Boston.

The study found that, compared to treatment with anti-arrhythmic drugs, radiofrequency catheter ablation significantly extended the time to first recurrence of AFib, atrial tachyarrhythmia, atrial flutter and asymptomatic AFib, in patients with paroxysmal recurrent AFib who had not been previously treated with an anti-arrhythmic drug. Paroxysmal atrial fibrillation is defined as recurrent (two or more) episodes of AFib that end spontaneously in less than seven days.

“This study supports consideration of catheter ablation as a first-line treatment option for patients with paroxysmal AFib,” said Carlos Morillo, M.D., FHRS, Hamilton Health Sciences-McMaster University, Hamilton, Canada, and co-principal investigator for the study. “This research is promising, as the results demonstrated better safety and effectiveness outcomes in AFib patients, not previously treated with drugs, who underwent radiofrequency ablation.”

Atrial fibrillation is the most common arrhythmia, or heart rhythm disorder. Other similar conditions include atrial tachyarrhythmia and atrial flutter. AFib is caused by disorganized electrical activity in the heart. Leading medical societies including the American Heart Association, American College of Cardiology and the European Society of Cardiology recommend catheter ablation as second-line therapy for AFib. The most common first-line treatment is anti-arrhythmia drugs; however, in certain patients they are not effective. Recent data indicate that more than 35 percent of patients will have recurrence of AFib despite best anti-arrhythmic drug therapy, and more than 30 percent of patients will discontinue the drugs because of adverse reactions.

Study Findings

The study, called First Line Radiofrequency Ablation versus Anti-arrhythmic Drugs for Atrial Fibrillation Treatment: A Multicenter Randomized Trial (RAAFT), was a multicenter, unblinded, parallel-arm clinical trial involving 127 patients with paroxysmal recurrent AFib. The study’s primary objective was to determine whether catheter ablation is superior to anti-arrhythmic drugs as a first-line therapy. A secondary endpoint was time to first occurrence of any event in a cluster of serious complications that occur in patients.

The study enrolled patients with a history of paroxysmal AFib. Participants were randomized into two groups, with 66 receiving pulmonary vein isolation using radiofrequency (RF) catheter ablation, and 61 receiving anti-arrhythmic drug therapy. Patients in the drug therapy arm were prescribed Dronedarone, Flecainide, Propafenone, Sotalol or Amiodarone.

The study patients were followed for two years. Catheter ablation was performed on day zero or the anti-arrhythmic drug therapy was optimized during the first 90 days. In a follow-up period from 90 days to 24 months, recurrence of symptomatic or asymptomatic paroxysmal atrial fibrillation, atrial flutter or atrial tachycardia was detected via intensive heart rhythm monitoring.

“This study demonstrated radiofrequency AFib ablation to be safe and superior to drug therapy in extending time to first recurrence of symptomatic or asymptomatic AFib, atrial tachyarrhythmia and atrial flutter, with a relative risk reduction of 44 percent [Hazard ratio = 0.56 (0.35 – 0.90), p= 0.016],” said Andrea Natale, M.D., FACC, FHRS, St. David’s Medical Center, Austin, Texas and co-principal investigator for the study. “In addition, the incidence of protocol-specified, treatment-related adverse safety events was 20 percent for the drug arm subjects vs. 8 percent for the RF ablation arm subjects.”

The study was sponsored by the Population Health Research Institute, McMaster University and Hamilton Health Sciences and funded by a research grant from Biosense Webster. Natale is compensated for his services as a member of the company’s scientific advisory board and provides other consulting services.

For more information: www.HRSonline.org

Related Content

Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Sponsored Content | Videos | Leads Implantable Devices| May 25, 2017
Bruce Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, discusses advancemen
Biotronik Home Monitoring implanted EP device remote wireless monitoring system
News | May 24, 2017
May 23, 2017 – Results now published in the European Heart Journal show Biotronik Home Monitoring reduces th
Sponsored Content | Videos | Pacemakers| May 23, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
Sponsored Content | Videos | Cardiac Resynchronization Therapy Devices (CRT)| May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Sponsored Content | Videos | Atrial Fibrillation| May 17, 2017
Hugh Calkins, M.D., FACC, FAHA, FHRS, director of cardiac arrhythmia services and professor of medicine at Johns Hopk
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Spectranetics Bridge Occlusion Balloon in the SVC

An illustration of how the Bridge balloon can seal the SVC after an accidental tear from lead extration.

Feature | EP Lab| May 17, 2017 | Dave Fornell
May 17, 2017 — A new intravenous occlusion balloon designed to seal any accidental tears in the superior vena cava (S
Overlay Init